Evidence map›Paper›PMID 40247137›Full record

ReviewEuropean journal of human genetics : EJHG2025

Vascular Ehlers Danlos Syndrome and Chromosome 2q32 Microdeletion Syndrome.

Claire E Green, Shadi Albaba, Glenda J Sobey, Jessica M Bowen, Deirdre E Donnelly, Marina Colombi, Marco Ritelli, Athalie Melville, Neeti Ghali, Fleur S van Dijk and 7 more

Abstract readReview
In one paragraph

Review in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Uncertainty, ethics, and progress in genomic medicine.European journal of human genetics : EJHG · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Claire E GreenEhlers-Danlos Syndrome National Diagnostic Service, Sheffield Children's Hospital, OPD2, Northern General Hospital, Sheffield, UK. Claire.green13@nhs.net.ORCID 0000-0003-0483-1197
Shadi AlbabaSheffield Diagnostic Genetics Service, Sheffield, UK.ORCID 0009-0007-2665-3850
Glenda J SobeyEhlers-Danlos Syndrome National Diagnostic Service, Sheffield Children's Hospital, OPD2, Northern General Hospital, Sheffield, UK.
Jessica M BowenEhlers-Danlos Syndrome National Diagnostic Service, Sheffield Children's Hospital, OPD2, Northern General Hospital, Sheffield, UK.
Deirdre E DonnellyNorthern Ireland Regional Genetics Centre, Belfast, Northern Ireland.
Marina ColombiDivision of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.ORCID 0000-0002-3105-5990
Marco RitelliDivision of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.ORCID 0000-0002-7025-2495
Athalie MelvilleWessex Clinical Genetics Service Level G, Princess Anne Hospital, Southampton, UK.
Neeti GhaliEhlers-Danlos Syndrome National Diagnostic Service, North West London Hospitals NHS Trust, Harrow, Middlesex, UK.ORCID 0000-0003-2847-1376
Fleur S van DijkEhlers-Danlos Syndrome National Diagnostic Service, North West London Hospitals NHS Trust, Harrow, Middlesex, UK.ORCID 0000-0001-6341-169X
Emma HobsonDepartment of Clinical Genetics, Chapel Allerton Hospital, Yorkshire Regional Genetics Service, Leeds, UK.
Jessica A RadleyNorth West Thames Regional Genetics Service, Harrow, Middlesex, UK.
Esther KinningWest Midlands Clinical Genetics Service, Clinical Genetics Unit, Birmingham Women's Hospital, Edgbaston, Birmingham, UK.
Abhijit DixitNottingham Clinical Genetics Department, The Gables, Nottingham City Hospital, Nottingham, UK.
Simon McCulloughNorthern Ireland Regional Genetics Centre, Belfast, Northern Ireland.
Duncan BakerSheffield Diagnostic Genetics Service, Sheffield, UK.
Diana S JohnsonEhlers-Danlos Syndrome National Diagnostic Service, Sheffield Children's Hospital, OPD2, Northern General Hospital, Sheffield, UK. Diana.johnson1@nhs.net.ORCID 0000-0002-8372-2716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interstitial deletions of 2q32 are typically identified after investigation for developmental delay. Two genes associated with Ehlers Danlos Syndrome (EDS); COL3A1 and COL5A2 associated with vascular EDS and classical EDS respectively, may be incorporated in the region. Although many reports of 2q32 microdeletion patients exist, there is little mention of these genes with only a few reports highlighting features potentially linked with EDS. This paper reviews the literature and presents eleven new patients with 2q32 deletions that encompass COL3A1 and COL5A2. We describe their clinical manifestations with a particular focus on the EDS phenotype. Most patients showed some minor features of vascular EDS and one patient had vessel rupture at a young age. Analysis of skin biopsy findings from two patients showed features consistent with vascular EDS but no features of classical EDS. The findings from this cohort provide additional evidence that haploinsufficiency is an important disease mechanism in COL3A1 but not COL5A2. We highlight the importance of pre-test counselling for incidental findings from broad genetic testing and appropriate post-test counselling to ensure follow up is provided to manage the implications of a vascular EDS diagnosis.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 2Ehlers-Danlos SyndromeAdolescentAdultChildChild, PreschoolCollagen Type IIICollagen Type VEhlers-Danlos Syndrome, Type IVFemaleHumansMalePhenotypeCOL3A1 protein, humanCollagen Type IIICollagen Type V

Identifiers

PMID40247137
PMCPMC12480010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.